Pancreatic Cancer – Oregovomab
Name of Protocol:
Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
CA-125 levels are not only elevated in ovarian cancer, but also in pancreatic cancer as well. The purpose of this 66-patient open label Phase 2 trial is to evaluate the efficacy of neoadjuvant chemotherapy, (gemcitabine [gemcitabine hydrochloride], leucovorin [leucovorin calcium], fluorouracil [5-FU]) with or without oregovomab, followed by hypo fractionated stereotactic radiotherapy (SRT) concurrently with nelfinavir (nelfinavir mesylate) in patients with locally advanced pancreatic cancer that is CA-125 positive (>= 10U/ml) or CA-125 negative (< 10U/ml).
Additional endpoints being studied are safety, and cellular and humoral immune responses to active immunotherapy with oregovomab in patients with pancreas cancer with CA-125 level greater than 10U/ml undergoing chemotherapy and radiation treatments.